

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | | |
|---|--|--|--|---|
| 1. Name and Address of Reporting Person * LUDVIGSON DAVID (Last) (First) (Middle) C/O BOSTON THERAPEUTICS, INC., 5900 HOLLIS STREET (Street) EMERYVILLE, CA 95608 (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year) 06/04/2021 | 3. Issuer Name and Ticker or Trading Symbol Boston Therapeutics, Inc. [BTHE] | | |
| | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <div style="border: 1px solid black; padding: 2px; display: inline-block;">CEO and President</div> | | 5. If Amendment, Date Original Filed (Month/Day/Year) |
| | | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person | | |

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|---|--|---|
| Common Stock, \$0.0001 par value per share | 0 | D | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|-----------------|---|----------------------------|--|---|---|
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |
| Series C Preferred Stock ⁽¹⁾ | 06/04/2021 | ⁽¹⁾ | Common Stock, \$0.0001 par value per share | 58,316,292 | \$ ⁽¹⁾ | D | |
| Warrants ⁽²⁾ | 06/04/2021 | 06/04/2026 | Common Stock, \$0.0001 par value per share | 6,503,659 | \$ 0.0034 | D | |
| Restricted Stock Units ⁽³⁾ | 06/04/2021 | 06/04/2031 | Common Stock, \$0.0001 par value per share | 181,809,374 | \$ 0 | D | |
| Incentive Stock Options ⁽⁴⁾ | 11/30/2012 | 11/30/2022 | Common Stock, \$0.0001 par value per share | 7,218,039 | \$ 0.0003 | D | |
| Incentive Stock Options ⁽⁴⁾ | 03/31/2014 | 03/31/2024 | Common Stock, \$0.0001 par value per share | 96,742,608 | \$ 0.0014 | D | |
| Incentive Stock Options ⁽⁴⁾ | 10/04/2016 | 10/04/2026 | Common Stock, \$0.0001 par value per share | 14,916,033 | \$ 0.0014 | D | |
| Incentive Stock Options ⁽⁴⁾ | 05/31/2017 | 05/31/2027 | Common Stock, \$0.0001 par value per share | 14,730,691 | \$ 0.0014 | D | |

| | | | | | | | |
|-----------------------------|------------|------------|--|------------|-----------|---|--|
| Incentive Stock Options (4) | 02/11/2020 | 02/11/2030 | Common Stock, \$0.0001 par value per share | 22,096,037 | \$ 0.0017 | D | |
|-----------------------------|------------|------------|--|------------|-----------|---|--|

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|-------------------|-------|
| | Director | 10% Owner | Officer | Other |
| LUDVIGSON DAVID C/O BOSTON THERAPEUTICS, INC. 5900 HOLLIS STREET EMERYVILLE, CA 95608 | X | | CEO and President | |

Signatures

| | | |
|---------------------------------|--|------------|
| /s/ David Ludvigson | | 06/30/2021 |
| **Signature of Reporting Person | | Date |

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- Each share of Series C Preferred Stock has a stated value of \$1.00 per share and is convertible into shares of common stock at a conversion rate of 6,066.044596 shares of
- (1) common stock for each share of Series C Preferred Stock. The shares of Series C Preferred Stock are automatically converted upon the filing of an amendment to the Company's certificate of incorporation implementing a reverse stock split.
 - (2) The shares underlying the warrants and the RSU may not be exercised until the implementation of a reverse stock split.
 - (3) RSUs vesting over 2 years
 - (4) Previously issued ISO stock options vested and unvested

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.